The University of Southampton
University of Southampton Institutional Repository

Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer

Leonard, R., Hardy, J., Van Tienhoven, G., Houston, S., Simmonds, P., David, M. and Mansi, J. (2001) Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer Journal of Clinical Oncology, 19, (21), pp. 4150-4159.

Record type: Article


Purpose: to compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer.
Patients and methods: in a double-blind, placebo-controlled, multicenter phase III study, a total of 52 patients with inoperable progressive skin lesions from histologically or cytologically confirmed breast cancer, not manageable by radiotherapy or systemic treatment, with superficial or flat skin lesions (estimated depth of invasion <= 1 cm) were randomized to receive either 6% miltefosine solution or placebo. The solution was applied at the dose of 2 drops/10 cm2, once daily during the first week and twice daily thereafter until treatment failure.
Results: treatment groups were well balanced for patient characteristics at study entry except for a small difference in age. Time to treatment failure (TTF), the primary parameter of this study, showed miltefosine solution to be significantly superior to placebo (P = .007); the median TTF in the miltefosine solution group was nearly three times longer than that in the placebo group (56 days v 21 days). The rate of response based on intention to treat patients was 33.3% for miltefosine solution compared with 3.7% for placebo (P = .006). Cutaneous reactions were seen mainly in the miltefosine group, with the type and frequency similar to those observed in previous studies.
Conclusion: 6% Miltefosine solution is confirmed as an effective palliative treatment option for cutaneous metastases from breast cancer. Skin reactions, when present, are well tolerated and only occasionally require cessation of treatment.

PDF 4150.pdf - Version of Record
Restricted to Repository staff only
Download (93kB)

More information

Published date: November 2001


Local EPrints ID: 26435
ISSN: 1527-7755
PURE UUID: 0ed1eb03-2b5b-4858-b37f-43951806e59c

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 17 Jul 2017 16:07

Export record


Author: R. Leonard
Author: J. Hardy
Author: G. Van Tienhoven
Author: S. Houston
Author: P. Simmonds
Author: M. David
Author: J. Mansi

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.